The system’s first approval was an FDA De Novo marketing authorization for the use of Anovo in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy. It is the first and only FDA-authorized surgical robotic platform that features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation.

The second generation Anovo platform, built on years of clinical insights, brings a suite of upgrades to enhance surgeon experience and ease of use, including the first FDA-cleared robotic system (single-port or multi-port) capable of operating in both retroflexion and anteflexion. The Anovo platform delivers unprecedented reach and articulation from a single incision. Surgeons can now also experience enhanced ergonomics with integrated haptic feedback, creating more intuitive control of the robotic arms during surgical procedures. Furthermore, a new annotation-enabled video overlay enhances in-room communication and supports teaching and collaboration among medical teams.

Ricardo E. Estape, MD, a practicing gynecology oncologist at Kendall Regional Medical Center and director of HCA Healthcare’s Institute for Gynecologic Oncology and long-time user of the Anovo system, praised the updated platform: “The additional features of the second-generation system really unlock the capabilities of the robot. The new controllers, haptic feedback and the floor mounted pedestal make the system extremely easy to use.”